New partnerships with Houston Research Institute and Knowledge Research Center will integrate AI-driven digital pathology for liver disease diagnostics.
HistoIndex announced the expansion of its commercial partnership network in the United States with the addition of two new hepatology and gastroenterology centers in Texas and California. The partnerships with Houston Research Institute Kingwood and Knowledge Research Center in Orange, California, aim to increase access to digital pathology solutions for Metabolic Dysfunction-associated Steatohepatitis (MASH).
HistoIndex is expanding diagnostic services to the Houston Research Institute Kingwood site, following a rollout across the Houston Research Institute system in late 2025. According to the company, the integration has improved workflows for biopsy sample preparation, evaluation for disease status, and logistical coordination with central labs.
“Over the past few months, we’ve seen how integrating HistoIndex’s solutions across our centers has streamlined their operational workflow for processing and shipping of liver biopsies, in addition to the markedly increased consistency we’ve observed in the biopsy interpretations by both traditional and AI-enhanced assessments offered by HistoIndex,” says Mazen Noureddin, MD, MHS, director at Houston Research Institute and co-chairman of the board at Summit and Pinnacle Clinical Research, in a release.
The partnership with Knowledge Research Center expands the reach of the diagnostic offering to the US West Coast. Knowledge Research Center is a medical center specializing in patient care and clinical trials for therapeutic areas including liver diseases.
“We are excited to partner with HistoIndex and integrate its AI-enhanced solutions into our clinical workflow,” says Alaa Abousaif, MD, co-founder of Knowledge Research Center, in a release.
MASH is a progressive form of Metabolic Dysfunction-associated Steatotic Liver Disease characterized by steatosis, ballooning degeneration, and inflammation. These conditions can lead to fibrosis, cirrhosis, and liver failure. While pathologist assessment of liver biopsy is the gold standard for diagnosis, HistoIndex notes that traditional scoring systems can be limited in capturing the complex and heterogeneous nature of the disease.
The company provides automated imaging solutions designed to quantify fibrosis in biological tissues. These tools are used to assist in the assessment of treatment response and disease severity in MASH.
